For instance, Kurppa KJ et al. find that re-expression of wild-type YAP1 in YAP1 KO EGFR-mutated NSCLC re-induces resistance to EGFR-TKIs osimertinib and trametinib [88]. Here, YAP1 is linked to non-small cell lung carcinoma.